Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic Transplantation of Haematopoietic Stem Cells Following Non-myeloablative Conditioning With Melphalan, Fludarabine, Thiotepa, Rituximab and Ibritumomab Tiuxetan (Zevalin) in Patients With Aggressive Non-Hodgkin's B-cell Lymphoma

NCT00644371 is registered in ClinicalTrials.gov with Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea as lead sponsor.

NCT NCT00644371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00644371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic Transplantation of Haematopoietic Stem Cells Following Non-myeloablative Conditioning With Melphalan, Fludarabine, Thiotepa, Rituximab and Ibritumomab Tiuxetan (Zevalin) in Patients With Aggressive Non-Hodgkin's B-cell Lymphoma
Lead sponsor
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2007
Completion date
February 4, 2013
Enrollment
20 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma